ClinicalTrials.gg
CompletedNCT01521650Updated Mar 10, 2021

Probiotics Against Pathogenic Bacteria in Connection With Anaesthesia

An interventional study of Probiotics in Oropharyngeal Microbiology, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Region Skane · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Longer surgical procedures require intubation and there is a potential risk of contaminating the lower airways with pathogenic bacteria from the mouth and oropharynx.

Healthy people seldom have pathogenic bacteria originating from the gastro-intestinal canal but those do occur among patients, both in those not so sick and patients with more severe problems.

For ICU patients we have seen a reduction of emerging enteric bacteria in patients given oral care with probiotics and this is a pilot study to explore the possibility of the same kind of positive effects in patients due for longer (more than 4 hours of anesthesia) procedures.

Randomisation

  • No prophylaxis
  • Preparation with a probiotic suspension before intubation.

Cultures

  • oropharynx

    • before treatment
    • after intubation
    • before extubation
    • day 1 postoperatively
  • tracheal secretions

    • after intubation
    • before extubation
02

Conditions studied

  • Oropharyngeal Microbiology

Keywords

  • Probiotics
  • Anaesthesia
  • Intubation
  • Pathogenic bacteria
03

In context

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients
  • Planned interventions
  • Anaesthesia > 4 hours and requiring intubation

Exclusion criteria

Exclusion Criteria:

  • Ulcers in the mouth, oropharynx, oesophagus and stomach
  • Current infections in the airways
  • Known immuno deficiences
  • Emergency cases
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Probiotics

    Patients will gurgle and swallow a mixture of probiotic bacteria

    Dietary Supplement: Probiotics

  • No intervention
    Control

    No intervention. What has been the standard procedure so far

Interventions

06

What researchers measure

Primary outcomes

  1. Differences in pathogenic bacteria in the oropharynx and lower airways

    Emerging and resident bacteria will be compared for the cultures taken in the oropharynx and from tracheal secretions in conection with anaestesia and a surgical intervention

    Time frame: During hospitalization, up to 4 weeks

Secondary outcomes

  1. White blood cells

    WBC taken pre-op and days 1,2,3 post-op

    Time frame: During hospitalization, up to 4 weeks

  2. CRP

    CRP taken pre-op and days 1,2,3 post-op

    Time frame: During hospitalization, up to 4 weeks

  3. Pneumonia

    X-ray verified infiltrations in combination with expectorates

    Time frame: Up till 7 days postoperatively

  4. Length of hospital stay

    Comparison of length of stay between the intervention group and the control group

    Time frame: time to discharged from hospital or patients death

07

Study locations

1 site
  • Lund University Hospital
    Lund, SE-22185, Sweden
08

References and documents

Publications

  • Stjernquist-Desatnik A, Warfving H, Johansson ML. Persistence of Lactobacillus plantarum DSM 9843 on human tonsillar surface after oral administration in fermented oatmeal gruel. A pilot study. Acta Otolaryngol Suppl. 2000;543:215-9. doi: 10.1080/000164800454422. PubMed 10909023 ↗
  • Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care. 2008;12(6):R136. doi: 10.1186/cc7109. Epub 2008 Nov 6. PubMed 18990201 ↗

Individual participant data

Plan to share: Yes — Results are intended to be published in a scientific journal

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Mar 2019 and a completion of Jul 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2012
First posted
Jan 31, 2012
Start
Jan 2012
Primary completionActual
Mar 2019
CompletionActual
Jul 2020
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01521650
Lead sponsor
Region Skane
Collaborators
Lund University
Responsible party
Bengt Klarin (MD Consultant, Region Skane) — Principal investigator
First posted
Jan 31, 2012
Start date
Jan 2012
Primary completion
Mar 2019
Completion
Jul 2020
Last update
Mar 10, 2021

Study contacts

Bengt klarin, MD PhD
principal investigator · Lund University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactobacillus plantarum 299

Start the discussion